SRR934888
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.730
- INTERFERON_GAMMA_RESPONSE+0.687
- E2F_TARGETS+0.600
- MYC_TARGETS_V1+0.568
- ALLOGRAFT_REJECTION+0.552
- G2M_CHECKPOINT+0.517
- MYC_TARGETS_V2+0.504
- IL6_JAK_STAT3_SIGNALING+0.466
- TNFA_SIGNALING_VIA_NFKB+0.433
- INFLAMMATORY_RESPONSE+0.432
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.414
- MYOGENESIS-0.336
- KRAS_SIGNALING_DN-0.335
- PANCREAS_BETA_CELLS-0.252
- SPERMATOGENESIS-0.127
- HEME_METABOLISM-0.092
- UV_RESPONSE_DN-0.087
- ESTROGEN_RESPONSE_EARLY-0.066
- WNT_BETA_CATENIN_SIGNALING-0.064
- APICAL_JUNCTION-0.052
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | FCD3124F-0F41-448E-B2B9-D9934D4EC1A7 | — | — | 0.952 |
| 2 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.951 |
| 3 | FD3CFD0E-E8D9-4A57-A9F0-4FB519B7E459 | — | — | 0.950 |
| 4 | 8B4E465B-0FD5-4154-824B-1E6B2656FD2F | — | — | 0.946 |
| 5 | B9535625-504A-4FCD-B341-2985AE72508A | — | — | 0.940 |
| 6 | SRR934883 | — | — | 0.940 |
| 7 | A43D720D-0CA3-48CF-ADC7-5AC72BD5EEA9 | — | — | 0.939 |
| 8 | AF548E30-7121-4F9F-A2CD-F1A540E9C4EE | — | — | 0.938 |
| 9 | 91E04630-B2A7-448E-8C80-580818C9D7E6 | — | — | 0.937 |
| 10 | D06FFD0C-80D4-413D-9C83-62D9C163EDAB | — | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.730 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.687 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.568 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.552 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.517 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.504 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.466 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.433 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.432 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.430 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.388 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.376 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.366 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.354 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.347 | Inavolisib | — uncovered |
| COMPLEMENT | 0.321 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.309 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.305 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |